ERS Genomics
ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of health care products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels, and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.comContent by ERS Genomics
Nobel prize winning CRISPR technology to be applied in development of genetically engineered cell and animal models
| 1 min read
License to Nobel prize-winning CRISPR technology supports internal research and development
| 1 min read
ZeClinics is applying CRISPR technology to create gene edited zebrafish disease models
| 1 min read
ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational patents covering CRISPR/Cas9
| 1 min read
The platform will be applied across Axxam’s integrated discovery services, in fields such as pharmaceuticals, crop protection, animal health, and food and beverages
| 1 min read
License agreement expands New England Biolabs’ rights to use and sell CRISPR/Cas9 reagents and tools
| 2 min read
ERS Genomics Limited and DefiniGEN Ltd announced a license agreement to provide DefiniGEN with access to ERS Genomic’s CRISPR/Cas9 genome editing technology patents
| 2 min read
Page 1 of 1 - 7 Total Items
